Related Experiment Video
Updated: Aug 7, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide
Uwe Lange1, Manfred Piegsa, Ulf Müller-Ladner
1Kerckhoff Clinic, University of Giessen, Department of Rheumatology and Clinical Immunology, Internal Medicine and Rheumatology, Bad Nauheim, Germany. u.lange@kerckhoff-klinik.de
Abstract:
Idiopathic inflammatory myopathies (IM), including dermatomyositis (DM) and polymyositis (PM), are a group of systemic rheumatologic diseases of unknown etiology characterized by chronic myositis. Antisynthetase antibodies such as the anti-Jo-1 antibody are known to be highly specific for inflammatory myopathies. Patients with this antibody frequently show a combination of symptoms including interstitial lung disease, fever, polyarthritis, myositis, Raynaud's phenomenon and "mechanic's hands". In the management of PM with anti-Jo-1 antibody, immunosuppressive agents are used to control the disease. Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis. Here, we report two cases of female patients with PM and anti-Jo-1 antibodies, who were successfully treated with leflunomide.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Myasthenia Gravis ll: Pathophysiology
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...